Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital
Clinical and Translational Science · 2026-05 · 19 (5)
DOI: 10.1111/cts.70579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 11.05.2026. Verfasst von Gayathri Baburaj und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Brain Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Lung cancer continues to be the leading cause of morbidity and mortality associated with malignancies. Identifying prognostic factors is vital for improving survival outcomes. This study assessed the impact of clinical, demographic, and genetic factors on overall survival (OS) and progression‐free survival (PFS) in patients with non‐small cell lung cancer (NSCLC). A prospective cohort of 70 NSCLC patients was analyzed. Demographic and clinical data, including epidermal growth factor receptor (EGFR) mutation status and clinical response by RECIST 1.1 criteria, were assessed. Survival outcomes were estimated using the Kaplan–Meier method with log‐rank test. The median PFS and OS were 15 and 24 months, respectively. EGFR‐positive patients showed significantly longer survival than EGFR‐negative patients (PFS: 17 vs. 11 months, OS: not reached [NA] vs. 24 months). Brain metastases indicated poor OS (OS: 15 months vs. NA) but did not affect PFS. Patients with a partial response after one year exhibited improved overall survival (24‐month OS probability of 77.8%). EGFR mutation status, brain metastases, and clinical response are key predictors of survival in NSCLC patients. Integrating genetic screening, timely management of brain metastases, and early assessment may enhance personalized treatment and improve prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.
- Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
- Department of Medical Oncology, Kasturba Medical College & Hospital, Manipal Academy of Higher Education, Manipal, Karnataka, India.
- Department of Data Science, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India.
ORCID-Profile: Gayathri Baburaj, Ananth Pai, Varun Kumar Sudha Gururaj, Satyanarayana Poojari, Mahadev Rao, Karthik S Udupa
Zitieren
APA
Baburaj, G., Pai, A., Sudha Gururaj, V. K., Poojari, S., Rao, M., & Udupa, K. S. (2026). Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70579
Vancouver
Baburaj G, Pai A, Sudha Gururaj VK, Poojari S, Rao M, Udupa KS. Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70579
BibTeX
@article{Baburaj2026,
author = {Baburaj, Gayathri and Pai, Ananth and Sudha Gururaj, Varun Kumar and Poojari, Satyanarayana and Rao, Mahadev and Udupa, Karthik S},
title = {Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {5},
doi = {10.1111/cts.70579}
}
EUVIMED